Selected article for: "open label and randomized trial"

Author: Arnold, Samuel L.M.; Buckner, Frederick
Title: Hydroxychloroquine for Treatment of SARS‐CoV‐2 Infection? Improving Our Confidence in a Model‐Based Approach to Dose Selection
  • Cord-id: 248de4cj
  • Document date: 2020_5_9
  • ID: 248de4cj
    Snippet: In less than six months, COVID-19 has spread from a marketplace in Wuhan, China to over 150 countries and territories of the world. Therapeutics are desperately needed to reduce the morbidity and mortality of this pandemic disease. It has been reported that hydroxychloroquine (HCQ) is active against SARS-CoV-2 in vitro, and this finding was quickly supported by an open label non-randomized clinical trial that provided the first published clinical evidence HCQ may be a treatment option.
    Document: In less than six months, COVID-19 has spread from a marketplace in Wuhan, China to over 150 countries and territories of the world. Therapeutics are desperately needed to reduce the morbidity and mortality of this pandemic disease. It has been reported that hydroxychloroquine (HCQ) is active against SARS-CoV-2 in vitro, and this finding was quickly supported by an open label non-randomized clinical trial that provided the first published clinical evidence HCQ may be a treatment option.

    Search related documents:
    Co phrase search for related documents
    • acidic compartment and lysosomal ph: 1
    • active therapeutic and lung epithelium: 1
    • additional concern and low concentration: 1